Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 124 of the 132 references it cites were found in a registry or an index; 72 of the 123 sources its claims cite were checked for support.

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists

Open access

Abstract

Guidelines for the management of obesity and type 2 diabetes (T2DM) emphasize the importance of lifestyle changes, including a reduced-calorie diet and increased physical activity. However, for many people, these changes can be difficult to maintain over the long term. Medication options are already available to treat obesity, which can help reduce appetite and/or reduce caloric intake. Incretin-based peptides exert their effect through G-protein-coupled receptors, the receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and glucagon peptide hormones are important regulators of insulin secretion and energy metabolism. Understanding the role of intercellular signaling pathways and inflammatory processes is essential for the development of effective pharmacological agents in obesity. GLP-1 receptor agonists have been successfully used, but it is assumed that their effectiveness may be limited by desensitization and downregulation of the target receptor. A growing number of new agents acting on incretin hormones are becoming available for everyday clinical practice, including oral GLP-1 receptor agonists, the dual GLP-1/GIP receptor agonist tirzepatide, and other dual and triple GLP-1/GIP/glucagon receptor agonists, which may show further significant therapeutic potential. This narrative review summarizes the therapeutic effects of different incretin hormones and presents future prospects in the treatment of T2DM and obesity.

Overview

CoChat Summary

TL;DR

This is a narrative review of incretin-based pharmacological treatments for obesity and type 2 diabetes, focusing on GLP-1 receptor agonists and newer dual/triple agonists. It argues that semaglutide and tirzepatide are effective, and that emerging agents like cotadutide, retatrutide, orforglipron, danuglipron, and cagrilintide-based combinations may expand treatment options, though long-term safety still needs study.

Key findings

  • In the STEP program, once-weekly semaglutide 2.4 mg produced about 15% weight loss in overweight/obese non-diabetic adults, and 9.6% weight loss in obese patients with T2DM (STEP-2).
  • In the SURMOUNT program, tirzepatide 15 mg weekly produced about 20% body-weight reduction in overweight/obese non-diabetic adults (SURMOUNT-1 and -3), and 14.7% in overweight/obese patients with T2DM (SURMOUNT-2).
  • In a 54-week study of 834 participants, cotadutide reduced HbA1c by −1.03% to −1.19% depending on dose; the highest dose lowered weight by −5.02 kg, compared with −3.33 kg for liraglutide 1.8 mg.
  • Orforglipron showed dose-dependent weight loss of up to 14.7% over 36 weeks in obese, non-diabetic individuals; danuglipron produced 1.2% HbA1c reduction and 4.2 kg weight loss over 16 weeks in T2DM, and a reported 11.7% weight loss over 32 weeks in obese non-diabetic individuals, but with >50% discontinuation due to adverse events in each dose group.

Methods

  • Narrative review summarizing therapeutic effects and future prospects of incretin-based therapies for obesity and T2DM.
  • Literature/data sources listed as PubMed, Scopus, Web of Science, and ClinicalTrials.gov, using keywords related to obesity, T2DM, incretin hormones, GPCRs, and dual/triple agonists.
  • The paper synthesizes results from clinical trials and preclinical studies; no original patient-level dataset or meta-analytic statistical model is reported.

Limitations

  • The paper does not report a systematic review protocol, study selection criteria, or risk-of-bias assessment; this is evident from the text, which describes a narrative review rather than a systematic review.
  • The authors explicitly note that for dual and triple GLP-1/GIP/glucagon agonists, safety needs assessment through cardiovascular outcome trials.
  • The text makes evident that many conclusions rely on early-phase or ongoing studies and that several mechanisms/effects remain unclear or need further investigation (for example, GIP effects on atherosclerosis, lipid metabolism, and energy expenditure).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/biomedicines12061320

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The incretin-based agents that are currently used in everyday medical practice or that are currently under clinical development [9].
Figure 1 The incretin-based agents that are currently used in everyday medical practice or that are currently under clinical development [9].CC BY · PubMed Central
Figure 2 Inflammatory mediators in adipose tissue, contributing to the development of chronic inflammatory conditions [11]. GLP-1: glucagon-like peptide-1; TNF-α: tumor necrosis factor-alpha; Th1cell: T-helper 1; Th2 cell: T-helper 2 cell; IL-1β: interleukin-1β; IL-4: interleukin-4; IL-6: interleukin-6; IL-10: interleukin-10.
Figure 2 Inflammatory mediators in adipose tissue, contributing to the development of chronic inflammatory conditions [11]. GLP-1: glucagon-like peptide-1; TNF-α: tumor necrosis factor-alpha; Th1cell: T-helper 1; Th2 cell: T-helper 2 cell; IL-1β: interleukin-1β; IL-4: interleukin-4; IL-6: interleukin-6; IL-10: interleukin-10.CC BY · PubMed Central
Figure 3 Activation of intracellular pathways by G-protein-coupled receptors and ligand binding, including G proteins, beta-arrestins, and other non-G-protein-regulated signaling pathways [20]. GLP-1: glucagon-like peptide-1.
Figure 3 Activation of intracellular pathways by G-protein-coupled receptors and ligand binding, including G proteins, beta-arrestins, and other non-G-protein-regulated signaling pathways [20]. GLP-1: glucagon-like peptide-1.CC BY · PubMed Central
Figure 4 The main effects of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon [9].
Figure 4 The main effects of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon [9].CC BY · PubMed Central
Figure 5 Clinical trials of subcutaneous semaglutide in overweight and obese individuals to evaluate weight loss efficacy (STEP 1–6, STEP-8, STEP Teens, STEP HFpEF).
Figure 5 Clinical trials of subcutaneous semaglutide in overweight and obese individuals to evaluate weight loss efficacy (STEP 1–6, STEP-8, STEP Teens, STEP HFpEF).CC BY · PubMed Central
Figure 6 Clinical trials of subcutaneous tirzepatide (SURMOUNT-1, -2 and -3 trials), retatrutide and cagrilintide, and oral semaglutide and orforglipron in overweight and obese subjects to evaluate weight reduction efficacy.
Figure 6 Clinical trials of subcutaneous tirzepatide (SURMOUNT-1, -2 and -3 trials), retatrutide and cagrilintide, and oral semaglutide and orforglipron in overweight and obese subjects to evaluate weight reduction efficacy.CC BY · PubMed Central
Figure 7 Clinical trials of subcutaneous tirzepatide, retatrutide, and cagrilintide/semaglutide in type 2 diabetic subjects to evaluate HbA1c reduction efficacy.
Figure 7 Clinical trials of subcutaneous tirzepatide, retatrutide, and cagrilintide/semaglutide in type 2 diabetic subjects to evaluate HbA1c reduction efficacy.CC BY · PubMed Central

Verification

Claims the paper makes

52 Valid · 10 Not valid · 36 Not checked · 18 Own results and interpretations

50 more claims · 24 with their cited sources checked

Create a free account to see all 116 claims and to verify the 8 references still open.

See all claims — free account
  • It may state two separate claims as one. 57
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Citations

Cites

Show all 132 references

Research works printed but not linked: 1

  1. Pfizer Inc. (2024, March 27). Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity. Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r.

Cited by

See all 47

Metadata

Authors
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M.
Affiliations
University of Debrecen (HU)
Corresponding author
Sztanek, Ferenc
Venue
Biomedicines
Publisher
MDPI AG
Published
2024-06-13
Volume
12
Issue
6
Pages
1320
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4399623216
Cited by
47
References
132
Citations by year
2026: 21 · 2025: 23 · 2024: 3
FWCI
2.34
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Research, Development and Innovation Office (K142273, TKP2021-EGA-18, 11003)
  • Ministry of Innovation and Technology of Hungary from the National Research (K142273, TKP2021-EGA-18, 11003)
  • Eötvös Loránd Research Network (K142273, TKP2021-EGA-18, 11003)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
obesity, type 2 diabetes, GLP-1 receptor agonists, incretin-based therapy, glucose-dependent insulinotropic polypeptide, tirzepatide, GIP/GLP-1 receptor agonist, glucagon receptor agonist, receptor desensitization, G protein-coupled receptors, appetite regulation, energy metabolism, inflammation, pharmacotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists. https://app.cochat.ai/papers/10.3390/biomedicines12061320
The paper
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024). New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists. Biomedicines. https://doi.org/10.3390/biomedicines12061320

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.